Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)

Introduction: Immune checkpoint inhibitors (ICIs) are now standard of care in many cancers. They can generate immune-related adverse events (irAEs), but no biomarkers are available to identify patients who are more likely to develop irAEs. We assess the association between pre-existing autoantibodie...

Full description

Saved in:
Bibliographic Details
Main Authors: A Daban, C Gonnin, L Phan, A Saldmann, C Granier, A Lillo-Lelouet, C Le Beller, J Pouchot, l Weiss, E Tartour, E Fabre, J Medioni, S Oudard, YA Vano, MA Dragon-Durey, A. Simonaggio
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:OncoImmunology
Subjects:
Immune checkpoint inhibitors
immune-related adverse events
pre-existing antibodies
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2023.2204754
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items